Following our latest publication, The Market for CRISPR/Cas9 Genome Editing Products, released in June 2015 on the Interactive Market Intelligence platform, a follow-up questionnaire was sent to The Science Advisory Board to quantify how the emergence of CRISPR/Cas9 technology is impacting the use of traditional tools and techniques. It was fielded between July 6-8, 2015.
To download, please go to: http://marketanalysts.lifescienceexecutive.com/blog/?p=1995
CRISPR is a new gene-editing technique that allows DNA to be precisely cut and replaced. Scientists are debating the ethics of using it to edit human embryos or genes that could be inherited by future generations. While CRISPR has potential medical benefits, its ability to "choose characteristics of future human generations" is controversial.
An Introduction to Crispr Genome EditingChris Thorne
In this short presentation, I make a case for doing genome editing vs some of the approaches that have gone before, describe some of the tools available, and the focus on CRISPR-Cas9, what it is, where it's come from and how it works.
CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MADiane McKenna
Key industry leaders will gather at the inaugural CRISPR Precision Gene Editing Congress with an ultimate purpose of addressing the importance of overcoming specificity, efficiency and delivery challenges associated with the CRISPR/Cas9 system. Pioneers will showcase the expanding biomedical and therapeutic potential of gene editing tools for drug discovery and development.
The key considerations of crispr genome editingChris Thorne
While CRISPR is simple to use, widely applicable and often highly efficient, there are a number of things to keep in mind to maximise experimental success. Here's what we recommend...
CRISPR is a new gene-editing tool that has significant promise but also requires regulation. It allows for precise editing of DNA by using guide RNA and an enzyme called Cas9. This advance enables basic scientists to create transgenic animal models, agricultural scientists to develop disease-resistant crops, and medical scientists to potentially cure and prevent genetic diseases. However, it also raises concerns about potential misuse by the military, wealthy individuals, or rogue scientists. As a result, CRISPR will be one of the biggest scientific issues of the next decade, and responsible innovation organizations should determine their stance, talk to researchers, work with governing bodies like NAS, and help convey both benefits and needed oversight of this technology.
2nd CRISPR Congress Boston, 23-25 February 2016 Diane McKenna
The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome.
CRISPR is a gene editing technology that has many applications in medicine, agriculture, and the environment. It works by using guide RNA and Cas9 protein to edit genes. In medicine, it shows promise for treating diseases like HIV/AIDS, muscular dystrophy, and cancer. In agriculture and environment, CRISPR can be used to develop crops that are more nutritious, resistant to climate change and pests, helping reduce hunger and poverty. While the prospects for CRISPR are good, there are also ethical concerns to consider regarding its use and effects. The future of CRISPR is limitless but it should be applied cautiously.
CRISPR is a new gene-editing technique that allows DNA to be precisely cut and replaced. Scientists are debating the ethics of using it to edit human embryos or genes that could be inherited by future generations. While CRISPR has potential medical benefits, its ability to "choose characteristics of future human generations" is controversial.
An Introduction to Crispr Genome EditingChris Thorne
In this short presentation, I make a case for doing genome editing vs some of the approaches that have gone before, describe some of the tools available, and the focus on CRISPR-Cas9, what it is, where it's come from and how it works.
CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MADiane McKenna
Key industry leaders will gather at the inaugural CRISPR Precision Gene Editing Congress with an ultimate purpose of addressing the importance of overcoming specificity, efficiency and delivery challenges associated with the CRISPR/Cas9 system. Pioneers will showcase the expanding biomedical and therapeutic potential of gene editing tools for drug discovery and development.
The key considerations of crispr genome editingChris Thorne
While CRISPR is simple to use, widely applicable and often highly efficient, there are a number of things to keep in mind to maximise experimental success. Here's what we recommend...
CRISPR is a new gene-editing tool that has significant promise but also requires regulation. It allows for precise editing of DNA by using guide RNA and an enzyme called Cas9. This advance enables basic scientists to create transgenic animal models, agricultural scientists to develop disease-resistant crops, and medical scientists to potentially cure and prevent genetic diseases. However, it also raises concerns about potential misuse by the military, wealthy individuals, or rogue scientists. As a result, CRISPR will be one of the biggest scientific issues of the next decade, and responsible innovation organizations should determine their stance, talk to researchers, work with governing bodies like NAS, and help convey both benefits and needed oversight of this technology.
2nd CRISPR Congress Boston, 23-25 February 2016 Diane McKenna
The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome.
CRISPR is a gene editing technology that has many applications in medicine, agriculture, and the environment. It works by using guide RNA and Cas9 protein to edit genes. In medicine, it shows promise for treating diseases like HIV/AIDS, muscular dystrophy, and cancer. In agriculture and environment, CRISPR can be used to develop crops that are more nutritious, resistant to climate change and pests, helping reduce hunger and poverty. While the prospects for CRISPR are good, there are also ethical concerns to consider regarding its use and effects. The future of CRISPR is limitless but it should be applied cautiously.
This document provides an overview of genome editing techniques such as CRISPR/Cas9 and rAAV and considerations for their use. It discusses how CRISPR/Cas9 and rAAV work to edit genomes and compares their advantages. Key factors for CRISPR gene editing are discussed such as gRNA design, donor design, and screening/validation approaches. The document also summarizes research optimizing CRISPR gene editing through improvements like testing different donor lengths and modifications. The goal is to translate genetic information into personalized medicines by leveraging tools like CRISPR and rAAV.
Recent breakthroughs in genome editing technology have led to a rapid adoption that parallels that seen with RNAi. And like RNAi, these methods are taking the scientific world by storm, with high profile publications in fields as diverse as HIV treatment, stem cell therapy, food crop modification and drug development to name but a few.
Critically, the endogenous modification of genes enables the study of their function in a physiological context. It also overcomes some of the artefacts that can result from established techniques such as transgenesis and RNAi, which have mislead researchers with false positives or negatives. Until recently however genome editing required considerable technical expertise, and consequently was a relatively niche pursuit.
In this talk we will look at how the latest developments in genome editing tools have changed this, with improvements in both ease-of-use and targeting efficiency, as well as a concomitant reduction in costs opening up these approaches to the wider scientific community.
Rapid adoption of the CRISPR/Cas9 system has for example led to a long list of organisms and tissues in which genetic changes have been made with high efficiency. Other technologies such as recombinant adeno-associated virus (rAAV) offer further precision, stimulating the cell’s high-fidelity DNA repair pathways to insert exogenous sequence with unrivalled specificity. Targeting efficiency can be improved still further by using the technologies in combination – genome cutting induced by CRISPR can significantly enhance homologous recombination mediated by rAAV.
Despite these rapid advances, some pitfalls remain, and so we’ll discuss some of the key considerations for avoiding these, ranging from simply picking the right tool for the job to designing an experiment that maximises chances of success.
Finally we’ll look at how genome editing is being applied to both basic and translational research, and in both a gene-specific and genome wide manner. For the study of disease associated genes and mutations scientists can now complement wide panels of tumour cells with genetically defined isogenic cell pairs identical in all but precise modifications in their gene of interest. The ease-of-design and efficiency of the CRISPR system is also being exploited for genome wide synthetic lethality screens, facilitating rapid drug target identification with significantly reduced risk of false negatives and off-target false positives. And again, further synergies are achieved when these approaches are combined to look for potential synthetic lethal targets in specific genomic contexts.
This document discusses the use of CRISPR gene editing technology. It provides examples of how CRISPR has been used to cure diseases in animals and potentially humans, create customized cancer models and modify animal organs. It also describes how CRISPR can be applied in agriculture to develop drought-resistant and pest-resistant crops, as well as in industrial biotechnology settings. The document then explains how gene drives work to alter genes and spread them through populations using CRISPR. It calls for responsible development of this technology through community guidance, transparency and democratic decision making.
The CRISPR/Cas9 system has emerged as one of the leading tools for modifying genomes of organisms ranging from E. coli to humans. Additionally, the simple gene targeting mechanism of CRISPR technology has been modified and adapted to other applications that include gene regulation, detection of intercellular trafficking, and pathogen detection. With a wealth of methods for introducing Cas9 and gRNAs into cells, it can be challenging to decide where to start. In this presentation, Dr Adam Clore describes the CRISPR mechanism and some of the most prominent uses for CRISPR, along with methods where IDT technologies can assist scientists in designing, testing, and executing a variety of CRISPR-mediated experiments. For more informaton, visit: http://www.idtdna.com/crispr
CRISPR-Cas9 is a powerful gene editing tool that has promising applications in public health. It allows targeted editing of genes and could help treat diseases like HIV/AIDS, cancer, and antibiotic resistance. However, there are also ethical concerns about its use, such as off-target effects and questions around human enhancement. Going forward, CRISPR holds potential for developing new therapies and improving agriculture, but its applications will require addressing safety, consent, and access issues.
Next-generation sequencing (NGS) has revolutionized the way we analyze diseases and commercial outfits such as Illumina, Helicos, QIAGEN and Pacific Biosciences have made significant contributions. In addition, the launch of direct-to-consumer genetic testing solutions has dramatically changed the way consumers access genomics data. Until a few years ago, the cost of sequencing was a major bottleneck. Recent developments have reduced the cost from thousands of dollars to a couple of cents per megabase. When did these changes start? What were the changes in the commercial sector in the last 15 years? This infographic is a timeline of the NGS commercial marketplace.
Researchers have developed new genome editing techniques that allow for rewriting genetic code with precision and efficiency similar to word processing. They demonstrated this by replacing codon instances in E. coli genomes. The techniques aim to add new functions, prevent cross-contamination of modified organisms, and establish viral resistance. Separately, other researchers have improved techniques for producing blood cells from human stem cells, achieving blood cell markers in 84% of cells using optimized growth conditions mimicking natural development. These techniques could enable new stem cell therapies for conditions like cancer and immune disorders.
CRISPR provides bacteria and archaea with adaptive immunity against bacteriophages. It works through a three step process: 1) recognition and adaptation of viral DNA fragments, 2) expression of CRISPR RNA, and 3) interference through the Cas9 endonuclease, which introduces double strand breaks in invading viral DNA. This mechanism can be harnessed for genome editing applications in eukaryotic cells. CRISPR also shows promise as a new approach to developing antimicrobial agents against superbugs by targeting pathogen-specific genes with unprecedented specificity. Developing resistance would be difficult for bacteria due to competition from phages.
Genome Editing Comes of Age; CRISPR, rAAV and the new landscape of molecular ...Candy Smellie
Information is no longer a bottleneck, emphasis is shifting to the ‘what does it all mean’
In a translational context we hope that by answering that question we will be able to is to characterise the genetics that drive disease, and indeed develop drugs and diagnostics that are personalised to patients.
Genome editing provides the link between the information here, and this outcome here, by allowing scientists to recapitulate specific genetic alterations in any gene in any living tissue to probe function, develop disease models and identify therapeutic strategies. So, not only do we now have unparalleled access to genetic information, but we now have the tools to most accuartely understand what this genetic information – with genome editing allowing us to explore the genetic drivers of disease in physiological models.
AAV is a single-stranded, linear DNA virus with a a 4.7 kb genome which for the purpose of genome editing is replaced almost in entirety with the targeting vector sequence (except for the iTRs)
It is in effect a highly effective DNA delivery mechanism
After entry of the vector into the cell, target-specific homologous DNA is believed to activate and recruit HR-dependent repair factors can induce HR at rates approximately 1,000 times greater than plasmid based double stranded DNA vectors, but the mechanism by which it achieves this is still largely unknown
By including a selection cassette can select for cells that have integrated the targeting vector, and then screen for clones which have undergone targeted insetion rather than random integration, which will generally be around 1%.
As a leading provider of gene editing service, Creative Biogene has launched a powerful CRISPR/Cas9 Platform. Our platform performs gene knockout/knockin programme with CRISPR/Cas9 system, from designing gRNA constructs to transfection and single clone generation of a wide range of cells, including difficult-to-transfect and tumor cell lines, as well as plants, mouse and other animal models.
When infected by virus, plants put up a defense!
The defense mechanism of Cassava when infected with CMV using a computational technique based on NGS high throughput sequencing data.
In this work, we aim to study the defense mechanism of Cassava
when infected with CMV using a computational technique based on
NGS high throughput sequencing data
1. Identify the small RNAs that are produced upon CMV infection
2. Predict the gene targets of these small RNAs
3. Compare the expression profiles of the susceptible clones with
respect to the resistant clones to CMD
CRISPR-Revolutionary Genome editing tools for Plants.....BHU,Varanasi, INDIA
CRISPR/Cas9 is a revolutionary genome editing tool discovered in bacterial immune systems. It provides acquired immunity against viruses and phages. CRISPR components include crRNA, tracrRNA, and Cas9 protein. There is an ongoing patent war over CRISPR between major scientists and institutions. CRISPR has been used to successfully edit plant genomes and develop disease resistant and drought tolerant crops like rice, cotton, wheat, and maize. It also shows promise for developing virus resistant varieties and removing unwanted plant species. CRISPR's applications extend to human health by potentially destroying cancer cells and disabling viruses like HIV.
CRISPR-Cas is a genome editing technique derived from bacterial immune systems that allows for precise genomic modifications. The document discusses applications of CRISPR-Cas in plants, animals, and bacteria, including developing pest and disease resistant crops and livestock, modifying stem cells and embryos, targeting antibiotic resistant bacteria, and controlling gene expression.
Speaker: Benedict C. S. Cross, PhD, Team leader (Discovery Screening), Horizon Discovery
CRISPR–Cas9 mediated genome editing provides a highly efficient way to probe gene function. Using this technology, thousands of genes can be knocked out and their function assessed in a single experiment. We have conducted over 150 of these complex and powerful screens and will use our experience to guide you through the process of screen design, performance and analysis.
We'll be discussing:
• How to use CRISPR screening for target ID and validation, understanding drug MOA and patient stratification
• The screen design, quality control and how to evaluate success of your screening program
• Horizon’s latest developments to the platform
• Horizon’s novel approaches to target validation screening
CRISPR-Cas9 mediated genome editing : A comprehensive review with zebrafish a...Arkaprava Roychaudhury
This document provides an overview of the CRISPR-Cas9 genome editing system. It discusses the history and mechanism of genome editing, describes the key components and mechanism of CRISPR-Cas9, and outlines its applications in research including in animal models like zebrafish. The document also discusses advantages and disadvantages of CRISPR-Cas9 as well as ethical issues and future prospects of this genome editing technique.
Transhumanismo y Mejoramiento Genético mediante CRISPRBioeticared
This document discusses CRISPR gene editing technology, including its origins and development, applications for therapeutic purposes, and debates around its use. It describes how CRISPR uses a guide RNA and Cas9 protein to cut DNA in a targeted way. While promising for treating genetic diseases, some argue its use in human embryos or germline cells raises safety and ethical issues due to risks of uncontrolled errors passing to future generations. Transhumanists support modifying the germline to induce enhanced traits, but this remains controversial.
This document discusses the potential benefits and risks of using CRISPR/Cas9 gene editing technology. Some key benefits discussed include its relatively low cost compared to other gene editing methods, its ability to efficiently and precisely edit genes, and recent successes using it to correct mutations that cause diseases like Duchenne Muscular Dystrophy in mice models. However, the document also notes potential risks like inducing unintended mutations, difficulties achieving a high enough editing rate, and risks of editing germline cells or human embryos. While promising for treating genetic diseases, the document argues that more research is still needed to minimize risks before clinical use, and that regulations will be important to guide its safe and ethical application.
GeneMind Biosciences specializes in developing molecular diagnosis technology through independent research and development of DNA sequencing systems. The company aims to build a precision medicine ecosystem through collaboration. GeneMind has launched two sequencing platforms, GenoCare 1600 for single molecule sequencing and GenoLab M for high throughput sequencing, offering a total solution. GeneMind is one of few companies worldwide with independent sequencing brands and core upstream technologies.
NOVEL ANALYTICAL TECHNOLOGIES FOR CHARACTERIZATION AND QC OF NEXT-GENERATION...iQHub
This document summarizes a presentation on novel analytical technologies for characterizing and quality controlling next-generation vaccines. It discusses how modern technologies have accelerated vaccine development. It then introduces several novel approaches for improving vaccine characterization, including the use of biosensors to accelerate purification and quality control of viral vectors. Finally, it presents a case study on implementing biosensors to improve productivity in downstream processing and quality control of adeno-associated viral vectors.
This document provides an overview of genome editing techniques such as CRISPR/Cas9 and rAAV and considerations for their use. It discusses how CRISPR/Cas9 and rAAV work to edit genomes and compares their advantages. Key factors for CRISPR gene editing are discussed such as gRNA design, donor design, and screening/validation approaches. The document also summarizes research optimizing CRISPR gene editing through improvements like testing different donor lengths and modifications. The goal is to translate genetic information into personalized medicines by leveraging tools like CRISPR and rAAV.
Recent breakthroughs in genome editing technology have led to a rapid adoption that parallels that seen with RNAi. And like RNAi, these methods are taking the scientific world by storm, with high profile publications in fields as diverse as HIV treatment, stem cell therapy, food crop modification and drug development to name but a few.
Critically, the endogenous modification of genes enables the study of their function in a physiological context. It also overcomes some of the artefacts that can result from established techniques such as transgenesis and RNAi, which have mislead researchers with false positives or negatives. Until recently however genome editing required considerable technical expertise, and consequently was a relatively niche pursuit.
In this talk we will look at how the latest developments in genome editing tools have changed this, with improvements in both ease-of-use and targeting efficiency, as well as a concomitant reduction in costs opening up these approaches to the wider scientific community.
Rapid adoption of the CRISPR/Cas9 system has for example led to a long list of organisms and tissues in which genetic changes have been made with high efficiency. Other technologies such as recombinant adeno-associated virus (rAAV) offer further precision, stimulating the cell’s high-fidelity DNA repair pathways to insert exogenous sequence with unrivalled specificity. Targeting efficiency can be improved still further by using the technologies in combination – genome cutting induced by CRISPR can significantly enhance homologous recombination mediated by rAAV.
Despite these rapid advances, some pitfalls remain, and so we’ll discuss some of the key considerations for avoiding these, ranging from simply picking the right tool for the job to designing an experiment that maximises chances of success.
Finally we’ll look at how genome editing is being applied to both basic and translational research, and in both a gene-specific and genome wide manner. For the study of disease associated genes and mutations scientists can now complement wide panels of tumour cells with genetically defined isogenic cell pairs identical in all but precise modifications in their gene of interest. The ease-of-design and efficiency of the CRISPR system is also being exploited for genome wide synthetic lethality screens, facilitating rapid drug target identification with significantly reduced risk of false negatives and off-target false positives. And again, further synergies are achieved when these approaches are combined to look for potential synthetic lethal targets in specific genomic contexts.
This document discusses the use of CRISPR gene editing technology. It provides examples of how CRISPR has been used to cure diseases in animals and potentially humans, create customized cancer models and modify animal organs. It also describes how CRISPR can be applied in agriculture to develop drought-resistant and pest-resistant crops, as well as in industrial biotechnology settings. The document then explains how gene drives work to alter genes and spread them through populations using CRISPR. It calls for responsible development of this technology through community guidance, transparency and democratic decision making.
The CRISPR/Cas9 system has emerged as one of the leading tools for modifying genomes of organisms ranging from E. coli to humans. Additionally, the simple gene targeting mechanism of CRISPR technology has been modified and adapted to other applications that include gene regulation, detection of intercellular trafficking, and pathogen detection. With a wealth of methods for introducing Cas9 and gRNAs into cells, it can be challenging to decide where to start. In this presentation, Dr Adam Clore describes the CRISPR mechanism and some of the most prominent uses for CRISPR, along with methods where IDT technologies can assist scientists in designing, testing, and executing a variety of CRISPR-mediated experiments. For more informaton, visit: http://www.idtdna.com/crispr
CRISPR-Cas9 is a powerful gene editing tool that has promising applications in public health. It allows targeted editing of genes and could help treat diseases like HIV/AIDS, cancer, and antibiotic resistance. However, there are also ethical concerns about its use, such as off-target effects and questions around human enhancement. Going forward, CRISPR holds potential for developing new therapies and improving agriculture, but its applications will require addressing safety, consent, and access issues.
Next-generation sequencing (NGS) has revolutionized the way we analyze diseases and commercial outfits such as Illumina, Helicos, QIAGEN and Pacific Biosciences have made significant contributions. In addition, the launch of direct-to-consumer genetic testing solutions has dramatically changed the way consumers access genomics data. Until a few years ago, the cost of sequencing was a major bottleneck. Recent developments have reduced the cost from thousands of dollars to a couple of cents per megabase. When did these changes start? What were the changes in the commercial sector in the last 15 years? This infographic is a timeline of the NGS commercial marketplace.
Researchers have developed new genome editing techniques that allow for rewriting genetic code with precision and efficiency similar to word processing. They demonstrated this by replacing codon instances in E. coli genomes. The techniques aim to add new functions, prevent cross-contamination of modified organisms, and establish viral resistance. Separately, other researchers have improved techniques for producing blood cells from human stem cells, achieving blood cell markers in 84% of cells using optimized growth conditions mimicking natural development. These techniques could enable new stem cell therapies for conditions like cancer and immune disorders.
CRISPR provides bacteria and archaea with adaptive immunity against bacteriophages. It works through a three step process: 1) recognition and adaptation of viral DNA fragments, 2) expression of CRISPR RNA, and 3) interference through the Cas9 endonuclease, which introduces double strand breaks in invading viral DNA. This mechanism can be harnessed for genome editing applications in eukaryotic cells. CRISPR also shows promise as a new approach to developing antimicrobial agents against superbugs by targeting pathogen-specific genes with unprecedented specificity. Developing resistance would be difficult for bacteria due to competition from phages.
Genome Editing Comes of Age; CRISPR, rAAV and the new landscape of molecular ...Candy Smellie
Information is no longer a bottleneck, emphasis is shifting to the ‘what does it all mean’
In a translational context we hope that by answering that question we will be able to is to characterise the genetics that drive disease, and indeed develop drugs and diagnostics that are personalised to patients.
Genome editing provides the link between the information here, and this outcome here, by allowing scientists to recapitulate specific genetic alterations in any gene in any living tissue to probe function, develop disease models and identify therapeutic strategies. So, not only do we now have unparalleled access to genetic information, but we now have the tools to most accuartely understand what this genetic information – with genome editing allowing us to explore the genetic drivers of disease in physiological models.
AAV is a single-stranded, linear DNA virus with a a 4.7 kb genome which for the purpose of genome editing is replaced almost in entirety with the targeting vector sequence (except for the iTRs)
It is in effect a highly effective DNA delivery mechanism
After entry of the vector into the cell, target-specific homologous DNA is believed to activate and recruit HR-dependent repair factors can induce HR at rates approximately 1,000 times greater than plasmid based double stranded DNA vectors, but the mechanism by which it achieves this is still largely unknown
By including a selection cassette can select for cells that have integrated the targeting vector, and then screen for clones which have undergone targeted insetion rather than random integration, which will generally be around 1%.
As a leading provider of gene editing service, Creative Biogene has launched a powerful CRISPR/Cas9 Platform. Our platform performs gene knockout/knockin programme with CRISPR/Cas9 system, from designing gRNA constructs to transfection and single clone generation of a wide range of cells, including difficult-to-transfect and tumor cell lines, as well as plants, mouse and other animal models.
When infected by virus, plants put up a defense!
The defense mechanism of Cassava when infected with CMV using a computational technique based on NGS high throughput sequencing data.
In this work, we aim to study the defense mechanism of Cassava
when infected with CMV using a computational technique based on
NGS high throughput sequencing data
1. Identify the small RNAs that are produced upon CMV infection
2. Predict the gene targets of these small RNAs
3. Compare the expression profiles of the susceptible clones with
respect to the resistant clones to CMD
CRISPR-Revolutionary Genome editing tools for Plants.....BHU,Varanasi, INDIA
CRISPR/Cas9 is a revolutionary genome editing tool discovered in bacterial immune systems. It provides acquired immunity against viruses and phages. CRISPR components include crRNA, tracrRNA, and Cas9 protein. There is an ongoing patent war over CRISPR between major scientists and institutions. CRISPR has been used to successfully edit plant genomes and develop disease resistant and drought tolerant crops like rice, cotton, wheat, and maize. It also shows promise for developing virus resistant varieties and removing unwanted plant species. CRISPR's applications extend to human health by potentially destroying cancer cells and disabling viruses like HIV.
CRISPR-Cas is a genome editing technique derived from bacterial immune systems that allows for precise genomic modifications. The document discusses applications of CRISPR-Cas in plants, animals, and bacteria, including developing pest and disease resistant crops and livestock, modifying stem cells and embryos, targeting antibiotic resistant bacteria, and controlling gene expression.
Speaker: Benedict C. S. Cross, PhD, Team leader (Discovery Screening), Horizon Discovery
CRISPR–Cas9 mediated genome editing provides a highly efficient way to probe gene function. Using this technology, thousands of genes can be knocked out and their function assessed in a single experiment. We have conducted over 150 of these complex and powerful screens and will use our experience to guide you through the process of screen design, performance and analysis.
We'll be discussing:
• How to use CRISPR screening for target ID and validation, understanding drug MOA and patient stratification
• The screen design, quality control and how to evaluate success of your screening program
• Horizon’s latest developments to the platform
• Horizon’s novel approaches to target validation screening
CRISPR-Cas9 mediated genome editing : A comprehensive review with zebrafish a...Arkaprava Roychaudhury
This document provides an overview of the CRISPR-Cas9 genome editing system. It discusses the history and mechanism of genome editing, describes the key components and mechanism of CRISPR-Cas9, and outlines its applications in research including in animal models like zebrafish. The document also discusses advantages and disadvantages of CRISPR-Cas9 as well as ethical issues and future prospects of this genome editing technique.
Transhumanismo y Mejoramiento Genético mediante CRISPRBioeticared
This document discusses CRISPR gene editing technology, including its origins and development, applications for therapeutic purposes, and debates around its use. It describes how CRISPR uses a guide RNA and Cas9 protein to cut DNA in a targeted way. While promising for treating genetic diseases, some argue its use in human embryos or germline cells raises safety and ethical issues due to risks of uncontrolled errors passing to future generations. Transhumanists support modifying the germline to induce enhanced traits, but this remains controversial.
This document discusses the potential benefits and risks of using CRISPR/Cas9 gene editing technology. Some key benefits discussed include its relatively low cost compared to other gene editing methods, its ability to efficiently and precisely edit genes, and recent successes using it to correct mutations that cause diseases like Duchenne Muscular Dystrophy in mice models. However, the document also notes potential risks like inducing unintended mutations, difficulties achieving a high enough editing rate, and risks of editing germline cells or human embryos. While promising for treating genetic diseases, the document argues that more research is still needed to minimize risks before clinical use, and that regulations will be important to guide its safe and ethical application.
GeneMind Biosciences specializes in developing molecular diagnosis technology through independent research and development of DNA sequencing systems. The company aims to build a precision medicine ecosystem through collaboration. GeneMind has launched two sequencing platforms, GenoCare 1600 for single molecule sequencing and GenoLab M for high throughput sequencing, offering a total solution. GeneMind is one of few companies worldwide with independent sequencing brands and core upstream technologies.
NOVEL ANALYTICAL TECHNOLOGIES FOR CHARACTERIZATION AND QC OF NEXT-GENERATION...iQHub
This document summarizes a presentation on novel analytical technologies for characterizing and quality controlling next-generation vaccines. It discusses how modern technologies have accelerated vaccine development. It then introduces several novel approaches for improving vaccine characterization, including the use of biosensors to accelerate purification and quality control of viral vectors. Finally, it presents a case study on implementing biosensors to improve productivity in downstream processing and quality control of adeno-associated viral vectors.
How we've made a global search engine for genetic dataMiro Cupak
The document summarizes how a global search engine for genetic data called Beacon Network was created through the development of federated query standards over multiple iterations. It started as a simple proof of concept in 2014 and now includes over 100 installations across 40 institutions and 18 countries, facilitating searches across datasets. The Beacon Network allows querying genetic data distributed across institutions for variants, genes, disorders and more, addressing the challenge of discovering insights from data too large for any single organization to hold.
The document discusses various imaging biomarkers and agents. It lists biomarkers such as DCE MRI, FDG PET, volumetric CT, and DWI MRI. It also lists several imaging agents targeting Alzheimer's disease (Florbetapir, Florbetaben, Flutemetamol), prostate cancer (MIP1404, PSMA minibody, CTT-54), and unstable cardiac plaques (FDG, TSPO GE-180, VasoPET, EP-2104R, P947). The document provides examples of each targeting area and discusses the relevant medical needs and solutions provided by the imaging agents.
Validazione dei cfDNA Test e Controlli di Qualità Esterni e InterniRoberto Scarafia
BREVE PREMESSA:
Negli ultimi anni si sono sviluppate tecnologie altamente sofisticate che consentono di valutare il rischio per condizioni cromosomiche fetali. L'ampio ventaglio di opzioni oramai disponibili nell'ambito degli screening non invasivi pone numerosi quesiti su quale tecnologia utilizzare e le problematiche specifiche connesse alla tecnologia. Durante questa mezza giornata di aggiornamento verranno dunque presentate in modo semplificato le basi molecolari delle differenti tecnologie coi vantaggi e vantaggi correlati, quali test sono disponibili e il loro livello di certificazione in relazione alla normativa europea inerente alla marchiatura CE-IVD, quali sono le cause di risultati discordanti, dei ‘no results’ e la gestione dei casi con risultato ad alto rischio, no result e discordanze
OBIETTIVI FORMATIVI:
• Descrivere le differenti tecnologie disponibili coi relativi vantaggi e svantaggi;
• Presentare le cause biologiche dei risultati discordanti mediante cfDNA test;
• Illustrare le diverse cause di ‘no result’ e le implicazioni sulle performances del test;
• Descrivere l’utilità delle certificazioni, validazioni dei cfDNA test e dei controlli esterni di
qualità;
• Discutere circa l’utilità clinica dei contenuti aggiuntivi oltre alle trisomie 21,18,13;
• Discutere circa il follow-up e il management dei risultati ad alto rischio, dei no results e dei
risultati discordanti.
Disruptors in the Medical Imaging IndustryBill Kelly
An overview of the Disruptors in the Medical Imaging Market. This free webinar will also give you more insight on the various factors that influence the market. We touch on results from a survey of a survey of 147 radiologists highlight the importance of reimbursement changes –both “appropriateness” measures and value-based medicine – as the most significant factors that will impact the imaging market.
A Fully Automated Sample-to-result PCR System for Detecting Infectious DiseasesSimon Chung - genereach
This document describes GeneReach Biotechnology Corporation's POCKIT Central system, a fully automated sample-to-result PCR system for infectious disease detection. The POCKIT Central can detect multiple pathogens from a single sample in less than 2 hours, including dengue virus serotypes. It has been validated against qPCR with equivalent sensitivity and specificity for dengue virus detection and subtyping. The portable and easy-to-use POCKIT Central provides a rapid and accurate molecular diagnostic solution for point-of-care infectious disease testing.
This document discusses strategies for delivering next generation cell therapy manufacturing faster without compromising quality. It summarizes Kite Pharma's dedication to cell therapy through vertical integration of critical functions. It also outlines the challenges of autologous cell therapy manufacturing due to its differences from conventional drug production. Automation, standardized processes across facilities, and coordination between manufacturing and healthcare providers are identified as ways to increase productivity and reliably treat more patients faster while maintaining high quality.
Deeper Insight into Transcriptomes! Download the FlyerQIAGEN
Discover a new workflow for RT-PCR-based gene expression work
Accurate and biologically relevant results in RT-PCR-based
gene expression can be difficult to achieve. Successful
transcriptome work requires validated, reproducible targets
and high-quality technology. Recognizing the variability arising from sample physiology
and pathology, the influence of sample purification and
assay conditions, and the importance of access to easyto-
use software, QIAGEN experts developed a new gene
expression workflow. It will help you properly validate your
RT-PCR and gain the deepest insight into your result.
The document outlines several challenges involved in technology transfer, noting that things like capital requirements, manufacturing processes, regulatory pathways, applications, market barriers, costs, and competitive landscapes are often unknown when transferring early stage technologies. It also provides an overview of technology readiness levels from basic principles being observed to full system demonstrations. Finally, it includes data on licensing activities and income for various universities and research institutions.
Steps to Overcome Information Overload in Clinical ResearchVeeva Systems
See slides from Veeva's Outsourcing Clinical Trials West Coast presentation.
This deck explores the driving forces behind the industrywide move to streamline information exchange in clinical trials. Learn about modern technologies that improve how organizations work together across the clinical environment and discover new approaches to sharing trial information with study partners.
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...Business Turku
This document provides an overview of PerkinElmer, a company focused on diagnostics, life sciences, food, and applied markets. It discusses their mission of innovating for a healthier world, with over 80 years of innovations including a COVID-19 PCR kit launched in 2020. The company's diagnostics segment focuses on reproductive health, immunoassays, and applied genomics. PerkinElmer has global capabilities across molecular diagnostics, imaging, automation, and more. It is pursuing growth in areas like single-cell analysis, therapeutics, digital solutions, and decentralized testing. The company's strategy focuses on detection, decentralization, and digitization to drive profitable growth.
Optimizing the Output of Your Molecular Pathology LaboratoryJosh Forsythe
If you are a clinical lab looking to build or accelerate your NGS testing capability where do you start? The components of success can be overwhelming - planning, assay design, validation, clinical lab workflow, informatics, and interpretation.
During this one-hour webinar, BG Jones, SVP of Business Development for PierianDx, who has 23 years of experience in healthcare IT and genomics technology, will demonstrate how to pull it all together using "Actionable Intelligence" - a combination of machine learning and human expertise to achieve clinically actionable insights.
The Pistoia Alliance is examining the challenges of the Faster Safe Companion Diagnostics (CDx) by Aligning Discovery & Clinical Data in the Regulatory Domain.
The slides discuss whether the data standards used in the research environment be aligned better with the data standards used in the regulated environment? If so, the time and cost of the development of NGS-based CDx could be reduced.
Astek Diagnostics is developing the Jiddu system, a rapid diagnostic test that can confirm bacterial infections and assess antibiotic sensitivity in urine, CSF, effluent, and blood samples in 1 hour. The company has completed over 400 urine-based tests with high accuracy. Its vision is for Jiddu to help address the growing problem of antibiotic resistance by providing fast, accurate, and easy-to-use diagnostics to guide treatment decisions. Astek is currently validating Jiddu for urine samples and has proof-of-concept data for other sample types. It expects FDA approval in 2025 and plans commercialization through distribution partners while retaining a focus on research and expanding the platform.
Roundup of This Year's AACC Meeting in AtlantaBruce Carlson
Major developments in point-of-care (POC) testing were highlighted at the 2015 American Association of Clinical Chemistry Annual Meeting:
1) Several companies announced new POC devices, including a low-cost, battery-powered molecular diagnostics platform from Cepheid and a smartphone-based chlamydia test.
2) Existing POC tests for influenza, diabetes, kidney disease, liver disease, and pregnancy from companies like Alere, DiaSys Diagnostics, and Abbott were demonstrated.
3) The large POC diagnostics market, estimated at $17 billion globally, was a focus for many exhibitors given the potential for rapid results at the point of care.
LIFE EXPECTANCY PREDICTION FOR POST THORACIC SURGERYIRJET Journal
This document discusses using machine learning algorithms to predict life expectancy after thoracic surgery. Researchers used attribute ranking and selection methods to identify the most important attributes from a dataset of patient health records. They evaluated algorithms like logistic regression and random forest on the reduced dataset. Logistic regression achieved the highest prediction accuracy of 85%. The goal was to more accurately predict mortality risk based on a patient's underlying health issues and attributes related to lung cancer.
Software as a Medical Device (SaMD) Challenges and Opportunities for 2021 and...Greenlight Guru
The SARS-CoV-2 pandemic drastically changes the landscape of digital health innovation. The FDA authorized emergency use for a variety of SaMD products including but not limited to mental health, clinical decision support and remote monitoring software applications. In addition, FDA recently launched the Digital Health Center of Excellence, provided updates on the pre-certification program, and host a session to convey FDA’s current thinking on AI/ML SaMD validation.
SaMD manufacturers must keep up with the fast-evolving regulatory landscape and optimize their software development practices with a goal to demonstrate conformance to the QMS requirements effectively and efficiently.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
DOES15 - Marc Hornbeek - Best Practices for Accelerating Continuous TestingGene Kim
Marc Hornbeek, Sr. Solutions Architect, Spirent
DevOps is all about Continuous Testing. Without CT there is no continuous delivery. This talk will explain how CT affects the success of DevOps and enumerates seven best practices that are essential for acceleration of Continuous Testing which include:
1. Team and culture specific to CT
2. CT System stability and metrics
3. Test tools integration
4. Accelerated test execution
5. CT-Ready tools
6. Fast and relevant test case analytics
7. Orchestration of test topologies
The talk concludes with a discussion of best practices assessments and a case study that shows the benefit of how a large enterprise benefited from CT acceleration.
hematic appreciation test is a psychological assessment tool used to measure an individual's appreciation and understanding of specific themes or topics. This test helps to evaluate an individual's ability to connect different ideas and concepts within a given theme, as well as their overall comprehension and interpretation skills. The results of the test can provide valuable insights into an individual's cognitive abilities, creativity, and critical thinking skills
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...Leonel Morgado
Current descriptions of immersive learning cases are often difficult or impossible to compare. This is due to a myriad of different options on what details to include, which aspects are relevant, and on the descriptive approaches employed. Also, these aspects often combine very specific details with more general guidelines or indicate intents and rationales without clarifying their implementation. In this paper we provide a method to describe immersive learning cases that is structured to enable comparisons, yet flexible enough to allow researchers and practitioners to decide which aspects to include. This method leverages a taxonomy that classifies educational aspects at three levels (uses, practices, and strategies) and then utilizes two frameworks, the Immersive Learning Brain and the Immersion Cube, to enable a structured description and interpretation of immersive learning cases. The method is then demonstrated on a published immersive learning case on training for wind turbine maintenance using virtual reality. Applying the method results in a structured artifact, the Immersive Learning Case Sheet, that tags the case with its proximal uses, practices, and strategies, and refines the free text case description to ensure that matching details are included. This contribution is thus a case description method in support of future comparative research of immersive learning cases. We then discuss how the resulting description and interpretation can be leveraged to change immersion learning cases, by enriching them (considering low-effort changes or additions) or innovating (exploring more challenging avenues of transformation). The method holds significant promise to support better-grounded research in immersive learning.
When I was asked to give a companion lecture in support of ‘The Philosophy of Science’ (https://shorturl.at/4pUXz) I decided not to walk through the detail of the many methodologies in order of use. Instead, I chose to employ a long standing, and ongoing, scientific development as an exemplar. And so, I chose the ever evolving story of Thermodynamics as a scientific investigation at its best.
Conducted over a period of >200 years, Thermodynamics R&D, and application, benefitted from the highest levels of professionalism, collaboration, and technical thoroughness. New layers of application, methodology, and practice were made possible by the progressive advance of technology. In turn, this has seen measurement and modelling accuracy continually improved at a micro and macro level.
Perhaps most importantly, Thermodynamics rapidly became a primary tool in the advance of applied science/engineering/technology, spanning micro-tech, to aerospace and cosmology. I can think of no better a story to illustrate the breadth of scientific methodologies and applications at their best.
ESPP presentation to EU Waste Water Network, 4th June 2024 “EU policies driving nutrient removal and recycling
and the revised UWWTD (Urban Waste Water Treatment Directive)”
Or: Beyond linear.
Abstract: Equivariant neural networks are neural networks that incorporate symmetries. The nonlinear activation functions in these networks result in interesting nonlinear equivariant maps between simple representations, and motivate the key player of this talk: piecewise linear representation theory.
Disclaimer: No one is perfect, so please mind that there might be mistakes and typos.
dtubbenhauer@gmail.com
Corrected slides: dtubbenhauer.com/talks.html
ESR spectroscopy in liquid food and beverages.pptxPRIYANKA PATEL
With increasing population, people need to rely on packaged food stuffs. Packaging of food materials requires the preservation of food. There are various methods for the treatment of food to preserve them and irradiation treatment of food is one of them. It is the most common and the most harmless method for the food preservation as it does not alter the necessary micronutrients of food materials. Although irradiated food doesn’t cause any harm to the human health but still the quality assessment of food is required to provide consumers with necessary information about the food. ESR spectroscopy is the most sophisticated way to investigate the quality of the food and the free radicals induced during the processing of the food. ESR spin trapping technique is useful for the detection of highly unstable radicals in the food. The antioxidant capability of liquid food and beverages in mainly performed by spin trapping technique.
The binding of cosmological structures by massless topological defectsSérgio Sacani
Assuming spherical symmetry and weak field, it is shown that if one solves the Poisson equation or the Einstein field
equations sourced by a topological defect, i.e. a singularity of a very specific form, the result is a localized gravitational
field capable of driving flat rotation (i.e. Keplerian circular orbits at a constant speed for all radii) of test masses on a thin
spherical shell without any underlying mass. Moreover, a large-scale structure which exploits this solution by assembling
concentrically a number of such topological defects can establish a flat stellar or galactic rotation curve, and can also deflect
light in the same manner as an equipotential (isothermal) sphere. Thus, the need for dark matter or modified gravity theory is
mitigated, at least in part.
Authoring a personal GPT for your research and practice: How we created the Q...Leonel Morgado
Thematic analysis in qualitative research is a time-consuming and systematic task, typically done using teams. Team members must ground their activities on common understandings of the major concepts underlying the thematic analysis, and define criteria for its development. However, conceptual misunderstandings, equivocations, and lack of adherence to criteria are challenges to the quality and speed of this process. Given the distributed and uncertain nature of this process, we wondered if the tasks in thematic analysis could be supported by readily available artificial intelligence chatbots. Our early efforts point to potential benefits: not just saving time in the coding process but better adherence to criteria and grounding, by increasing triangulation between humans and artificial intelligence. This tutorial will provide a description and demonstration of the process we followed, as two academic researchers, to develop a custom ChatGPT to assist with qualitative coding in the thematic data analysis process of immersive learning accounts in a survey of the academic literature: QUAL-E Immersive Learning Thematic Analysis Helper. In the hands-on time, participants will try out QUAL-E and develop their ideas for their own qualitative coding ChatGPT. Participants that have the paid ChatGPT Plus subscription can create a draft of their assistants. The organizers will provide course materials and slide deck that participants will be able to utilize to continue development of their custom GPT. The paid subscription to ChatGPT Plus is not required to participate in this workshop, just for trying out personal GPTs during it.
Immersive Learning That Works: Research Grounding and Paths ForwardLeonel Morgado
We will metaverse into the essence of immersive learning, into its three dimensions and conceptual models. This approach encompasses elements from teaching methodologies to social involvement, through organizational concerns and technologies. Challenging the perception of learning as knowledge transfer, we introduce a 'Uses, Practices & Strategies' model operationalized by the 'Immersive Learning Brain' and ‘Immersion Cube’ frameworks. This approach offers a comprehensive guide through the intricacies of immersive educational experiences and spotlighting research frontiers, along the immersion dimensions of system, narrative, and agency. Our discourse extends to stakeholders beyond the academic sphere, addressing the interests of technologists, instructional designers, and policymakers. We span various contexts, from formal education to organizational transformation to the new horizon of an AI-pervasive society. This keynote aims to unite the iLRN community in a collaborative journey towards a future where immersive learning research and practice coalesce, paving the way for innovative educational research and practice landscapes.